BeiGene Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (31)

Latest Posts

About This Stock More About This Stock
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Article By: Zacks Investment Research
Sunday, January 7, 2024 9:00 AM EST
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech stocks that will likely perform well in 2024.
In this article: REGN, SRPT, BGNE
Read
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Article By: ChinaBio® Today
Saturday, November 25, 2023 1:40 PM EST
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront payment, plus milestones and royalties.
In this article: BGNE Also: AZN, WXXWY, CNTB
Read
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
Article By: ChinaBio® Today
Saturday, October 21, 2023 1:39 PM EST
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin platform to Almirall in a $210 million agreement.
In this article: SRXXF, BGNE, WXXWY, ASPHF, NVO, LBTSF, TAK
Read
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Article By: ChinaBio® Today
Saturday, September 23, 2023 2:19 PM EST
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make an upfront payment of $7 million to Kezar.
In this article: NVS, BGNE, KZR Also: BMY, OCUL
Read
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
Article By: ChinaBio® Today
Saturday, August 12, 2023 2:39 PM EST
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies raised $100 million in a private placement.
In this article: BGNE, GRCL Also: BMY, SBHMY, AZN, CASBF, BNTX, JBPHF
Read

Latest Tweets for $BGNE

No tweets yet!

PARTNER HEADLINES

$BGNE

The World Has Turned Sunny
Marcy Brown 11/10/2020 2:19:18 AM

I don't really understand why $BGNE was downrated. The news was positive.

1 to 1 of 1 comments